| 國立臺灣大學 |
2006-02 |
Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy
|
Sheng, WH (Sheng, Wang-Huei); Hung, CC (Hung, Chien-Ching); Wu, RJ (Wu, Ruei-Jiuan); Wang, JT (Wang, Jann-Tay); Chen, PJ (Chen, Pei-Jer); Chang, SC (C |
| 臺大學術典藏 |
2018-09-10T06:27:52Z |
Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy
|
SHAN-CHWEN CHANG; JIA-HORNG KAO; JANN-TAY WANG; CHIEN-CHING HUNG; Sheng, W.-H. and Hung, C.-C. and Wu, R.-J. and Wang, J.-T. and Chen, P.-J. and Chang, S.-C. and Kao, J.-H.; PEI-JER CHEN; WANG-HUEI SHENG |
| 臺大學術典藏 |
2020-09-30T03:23:05Z |
Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy
|
Kao J.-H.; Chang S.-C.; Chen P.-J.; Wang J.-T.; Sheng W.-H.;Chien-Ching Hung;Wu R.-J.;Wang J.-T.;Chen P.-J.;Chang S.-C.;Kao J.-H.; Sheng W.-H.; CHIEN-CHING HUNG; Wu R.-J. |
| 臺大學術典藏 |
2020-12-29T03:08:52Z |
Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy
|
Sheng W.-H.;Hung C.-C.;Wu R.-J.;Jann-Tay Wang;Chen P.-J.;Chang S.-C.;Kao J.-H.; Kao J.-H.; Sheng W.-H.; Hung C.-C.; Wu R.-J.; JANN-TAY WANG; Chen P.-J.; Chang S.-C. |
| 臺大學術典藏 |
2021-07-03T03:35:07Z |
Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy
|
Sheng W.-H.; Hung C.-C.; Wu R.-J.; Wang J.-T.; PEI-JER CHEN; Chang S.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-05-13T08:05:08Z |
Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy
|
Sheng W.-H.; Hung C.-C.; Wu R.-J.; JANN-TAY WANG; Chen P.-J.; Chang S.-C.; Kao J.-H. |
| 國立臺灣大學 |
2007-11 |
Clinical impact of GB virus C viremia on patients with human immunodeficiency virus type 1 infection in the era of highly active antiretroviral therapy.
|
Sheng, WH; Hung, CC; Wang, RJ; Wang, JT; Chen, PJ; Chang, SC; Kao, JH. |
| 臺大學術典藏 |
2021-07-22T06:25:01Z |
Clinical impact of irreversible electroporation ablation for unresectable hilar cholangiocarcinoma
|
CHIH-YANG HSIAO; Yang P.-C.; Li X.; Huang K.-W. |
| 臺大學術典藏 |
2021-04-29T06:52:42Z |
Clinical impact of irreversible electroporation ablation for unresectable hilar cholangiocarcinoma
|
Hsiao, Chih-Yang;Yang, Po-Chih;Li, Xiaoyong;Kai-Wen Huang; Hsiao, Chih-Yang; Yang, Po-Chih; Li, Xiaoyong; KAI-WEN HUANG |
| 中山醫學大學 |
2020 |
Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
|
Chen, YY; Wang, CC; Liu, YW; Li, WF; Chen, YH |
